Page last updated: 2024-10-22

anastrozole and Carcinoma, Lobular

anastrozole has been researched along with Carcinoma, Lobular in 20 studies

Carcinoma, Lobular: A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.

Research Excerpts

ExcerptRelevanceReference
"27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer."9.27Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018)
"Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women."9.19Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014)
" We report an unusual case of urticarial vasculitis following the aromatase inhibitor anastrozole that localised to the unilateral trunk and mastectomy scar, and review the literature on the cutaneous adverse effects of hormonal therapy for breast cancer."8.90Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. ( Bock, VL; Friedlander, M; Kossard, S; Waring, D; Wood, GK, 2014)
"A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)."7.83Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016)
"27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer."5.27Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018)
"Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women."5.19Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014)
" We report an unusual case of urticarial vasculitis following the aromatase inhibitor anastrozole that localised to the unilateral trunk and mastectomy scar, and review the literature on the cutaneous adverse effects of hormonal therapy for breast cancer."4.90Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. ( Bock, VL; Friedlander, M; Kossard, S; Waring, D; Wood, GK, 2014)
"A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)."3.83Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016)
"Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer."3.80Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. ( Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M, 2014)
"We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil."3.73t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006)
"Although approximately 60 % of breast cancers in premenopausal women are HR positive, the role of neoadjuvant ET in this population is not well defined."1.42Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. ( Barbie, TU; Ma, C; Margenthaler, JA, 2015)
"Breast cancer is the most frequent primary site of metastasis to the uterine corpus, with invasive lobular carcinoma more likely to spread to gynecologic organs than invasive ductal carcinoma."1.42Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report. ( Akagi, K; Hayasaka, A; Igeta, S; Ishigaki, N; Iwahashi, H; Kudo, T; Makino, H; Matsuura, R; Sakurada, J; Shima, T; Suzuki, H; Toyoshima, M; Yoshinaga, K, 2015)
"The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008."1.38Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012)
"Rectal metastases from breast carcinomas are very rare."1.36Rectal metastasis from lobular carcinoma of the breast: a case report. ( Balja, MP; Knezević, F; Sitić, S; Stanec, M; Supić, DK; Vrdoljak, DV, 2010)
"Lobular carcinoma is the most common type of breast cancer that metastasizes to the uterus."1.35Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy. ( Barisik, NO; Bilici, A; Gumus, M; Salepci, T; Salman, T; Seker, M; Ustaalioglu, BB; Yaylaci, M, 2009)
"This is the first report of breast carcinoma metastatic to the endometrium in a patient on adjuvant anastrozole therapy."1.33Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy. ( Bolat, F; Erkanli, S; Haberal, A; Kayaselcuk, F; Kuscu, E; Sakalli, H, 2006)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (30.00)29.6817
2010's14 (70.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Strasser-Weippl, K1
Sudan, G1
Ramjeesingh, R1
Shepherd, LE1
O'Shaughnessy, J1
Parulekar, WR1
Liedke, PER1
Chen, BE1
Goss, PE1
Sathiamoorthi, S1
Ruddy, KJ1
Bakri, SJ1
Cameron, DA1
Cuzick, J1
Sestak, I1
Forbes, JF1
Dowsett, M2
Knox, J1
Cawthorn, S1
Saunders, C1
Roche, N1
Mansel, RE1
von Minckwitz, G1
Bonanni, B1
Palva, T1
Howell, A1
Grassadonia, A1
Di Nicola, M1
Grossi, S1
Noccioli, P1
Tavoletta, S1
Politi, R1
Angelucci, D1
Marinelli, C1
Zilli, M1
Ausili Cefaro, G1
Tinari, N1
De Tursi, M1
Iezzi, L1
Cioffi, P1
Iacobelli, S1
Natoli, C1
Cianchetti, E1
Bock, VL1
Friedlander, M1
Waring, D1
Kossard, S1
Wood, GK1
Barbie, TU1
Ma, C1
Margenthaler, JA1
Toyoshima, M1
Iwahashi, H1
Shima, T1
Hayasaka, A1
Kudo, T1
Makino, H1
Igeta, S1
Matsuura, R1
Ishigaki, N1
Akagi, K1
Sakurada, J1
Suzuki, H1
Yoshinaga, K1
Egawa, C1
Hirokaga, K1
Takao, S1
Yamagami, K1
Miyashita, M1
Baba, M1
Ichii, S1
Konishi, M1
Kikawa, Y1
Minohata, J1
Okuno, T1
Miyauchi, K1
Wakita, K1
Suwa, H1
Hashimoto, T1
Nishino, M1
Matsumoto, T1
Hidaka, T1
Konishi, Y1
Sakoda, Y1
Miya, A1
Mitsunobu, M1
Nishikawa, H1
Kono, S1
Kokufu, I1
Sakita, I1
Kitatsuji, K1
Oh, K1
Miyoshi, Y1
Sansone, P1
Ceccarelli, C1
Berishaj, M1
Chang, Q1
Rajasekhar, VK1
Perna, F1
Bowman, RL1
Vidone, M1
Daly, L1
Nnoli, J1
Santini, D1
Taffurelli, M1
Shih, NN1
Feldman, M1
Mao, JJ1
Colameco, C1
Chen, J1
DeMichele, A1
Fabbri, N1
Healey, JH1
Cricca, M1
Gasparre, G1
Lyden, D1
Bonafé, M1
Bromberg, J1
Lerebours, F1
Rivera, S1
Mouret-Reynier, MA1
Alran, S1
Venat-Bouvet, L1
Kerbrat, P1
Salmon, R1
Becette, V1
Bourgier, C1
Cherel, P1
Boussion, V1
Balleyguier, C1
Thibault, F1
Lavau-Denes, S1
Nabholz, JM1
Sigal, B1
Trassard, M1
Mathieu, MC1
Martin, AL1
Lemonnier, J1
Mouret-Fourme, E1
Ustaalioglu, BB1
Bilici, A1
Seker, M1
Salman, T1
Gumus, M1
Barisik, NO1
Salepci, T1
Yaylaci, M1
Balja, MP1
Vrdoljak, DV1
Stanec, M1
Sitić, S1
Supić, DK1
Knezević, F1
Prowell, TM1
Blackford, AL1
Byrne, C1
Khouri, NF1
Folkerd, E1
Tarpinian, KS1
Powers, PP1
Wright, LA1
Donehower, MG1
Jeter, SC1
Armstrong, DK1
Emens, LA1
Fetting, JH1
Wolff, AC1
Garrett-Mayer, E1
Skaar, TC1
Davidson, NE1
Stearns, V1
Wink, CJ1
Woensdregt, K1
Nieuwenhuijzen, GA1
van der Sangen, MJ1
Hutschemaekers, S1
Roukema, JA1
Tjan-Heijnen, VC1
Voogd, AC1
Erkanli, S1
Kayaselcuk, F1
Kuscu, E1
Bolat, F1
Sakalli, H1
Haberal, A1
Zapata, E1
Zubiaurre, L1
Bujanda, L1
Piérola, A1
Goodwin, GM1
Resnik, KS1
DiLeonardo, M1
Gibbons, G1
Sahin, FI1
Yilmaz, Z1
Karakuş, S1
Boğa, S1
Akçali, Z1
DemIrhan, B1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00066573]Phase 37,576 participants (Actual)Interventional2003-06-06Completed
International Breast Cancer Intervention Study[NCT00078832]Phase 33,864 participants (Actual)Interventional2003-09-30Completed
Effects of Progressive Relaxation Training on Artralgia, Quality of Life and Emotional Status in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy[NCT04163692]44 participants (Actual)Interventional2019-10-25Completed
A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.[NCT00629616]Phase 2116 participants (Actual)Interventional2007-10-31Completed
Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy[NCT00244959]Phase 254 participants (Actual)Interventional2004-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Fracture Rate: Number of Participants With Bone Fractures.

Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures. (NCT00066573)
Timeframe: 8 years

InterventionParticipants (Count of Participants)
Exemestane358
Anastrozole354

Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence

Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver. (NCT00066573)
Timeframe: 5 years

InterventionParticipants (Count of Participants)
Exemestane157
Anastrozole164

Event-free Survival

Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. (NCT00066573)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Exemestane88
Anastrozole89

Overall Survival: Percentage of Participants Alive at 5 Years

Overall survival is defined as the time from randomization to the time of death from any cause. (NCT00066573)
Timeframe: 5 years

InterventionPercentage of Participants (Number)
Exemestane92
Anastrozole92

Reviews

1 review available for anastrozole and Carcinoma, Lobular

ArticleYear
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
    The Australasian journal of dermatology, 2014, Volume: 55, Issue:4

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Chemothera

2014

Trials

3 trials available for anastrozole and Carcinoma, Lobular

ArticleYear
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 90

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms

2018
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C

2014
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C

2014
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C

2014
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C

2014
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
    Cancer, 2016, Volume: 122, Issue:19

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas

2016

Other Studies

16 other studies available for anastrozole and Carcinoma, Lobular

ArticleYear
Association of Uveitis and Macular Edema With Anastrozole Therapy.
    JAMA ophthalmology, 2018, 07-01, Volume: 136, Issue:7

    Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Fluorescein A

2018
Breast cancer chemoprevention: little progress in practice?
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc

2014
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
    Annals of surgical oncology, 2014, Volume: 21, Issue:5

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo

2014
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Annals of surgical oncology, 2015, Volume: 22, Issue:12

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;

2015
Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report.
    Journal of medical case reports, 2015, Feb-14, Volume: 9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobula

2015
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
    International journal of clinical oncology, 2016, Volume: 21, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duct

2016
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
    Nature communications, 2016, Feb-09, Volume: 7

    Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal;

2016
Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
    Onkologie, 2009, Volume: 32, Issue:7

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Diagnosis, Diffe

2009
Rectal metastasis from lobular carcinoma of the breast: a case report.
    Collegium antropologicum, 2010, Volume: 34, Issue:2

    Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobula

2010
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
    Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:12

    Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcin

2011
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
    Annals of surgical oncology, 2012, Volume: 19, Issue:4

    Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla

2012
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
    Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc

2006
Anastrozole-induced hepatotoxicity.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:11

    Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla

2006
Aromatase inhibitors and bipolar mood disorder: a case report.
    Bipolar disorders, 2006, Volume: 8, Issue:5 Pt 1

    Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobula

2006
Clinically occult cutaneous metastases.
    Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6

    Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon

2006
t(8;16) AML developed subsequent to breast cancer therapy.
    Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M

2006